Based on recent evidence showing the presence of ERα in lymphatic endothelial cells, it is reasonable to postulate that SERMs and/or Aromatase Inhibitors could have an impact on lymphatic-related breast cancer side effects such as lymphedema [15]. Here, ESR1 is linked to breast cancer.